Hidroaltesona (Hydrocortisone)

Hidroaltesona is indicated for several medical conditions that benefit from glucocorticoid activity. It is prescribed by healthcare professionals based on individual patient needs.

• Replacement therapy for adrenal insufficiency such as Addison's disease.
• Management of inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus).
• Treatment of severe allergic reactions, including anaphylaxis adjunct therapy.
• Control of acute exacerbations of chronic inflammatory diseases.
• Supportive care in certain endocrine disorders requiring glucocorticoid supplementation.

• Hydrocortisone, the active ingredient in Hidroaltesona, binds to intracellular glucocorticoid receptors, forming a hormone‑receptor complex that translocates to the nucleus. This complex modulates gene transcription, up‑regulating anti‑inflammatory proteins (such as annexin‑1) and down‑regulating pro‑inflammatory cytokines, chemokines, and adhesion molecules. The net effect is reduced leukocyte infiltration, decreased vascular permeability, and suppression of immune responses, providing anti‑inflammatory and immunosuppressive actions.

Adverse reactions to Hidroaltesona can vary in frequency and severity. Patients should be aware of both common and serious potential effects.

Common

• Increased appetite or weight gain.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels.
• Mood changes such as irritability or anxiety.
• Gastrointestinal discomfort or dyspepsia.

Serious

• Severe hyperglycemia or new‑onset diabetes.
• Osteoporosis or increased fracture risk.
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis.
• Opportunistic infections due to immunosuppression.
• Peptic ulcer disease or gastrointestinal bleeding.

Before starting Hidroaltesona, certain health considerations should be reviewed with a healthcare provider.

• Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Evaluate bone health, especially in patients with osteoporosis risk factors.
• Monitor blood glucose in diabetic or pre‑diabetic individuals.
• Use caution in patients with hypertension, heart failure, or renal impairment.
• Discuss any history of psychiatric disorders, as steroids may affect mood.
• Inform the prescriber of any planned vaccinations, particularly live vaccines.

Hidroaltesona may interact with other medicines, altering its efficacy or safety profile.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone levels.
• Combining with other systemic glucocorticoids, which can increase the risk of adrenal suppression.
• Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) without monitoring, due to heightened gastrointestinal bleeding risk.

Use with caution

• Anticoagulants (e.g., warfarin) as glucocorticoids may affect clotting parameters.
• Antidiabetic agents, because hydrocortisone can raise blood glucose.
• Vaccines, particularly live attenuated vaccines, due to immunosuppressive effects.
• Diuretics, which may exacerbate fluid retention and electrolyte disturbances.